• Home
  • NEW DAY MEDICINE
  • 9 (59) 2023
  • 62 -9 (59) 2023 — Oblokulov Abdurashid Rakhimovich — THE SIGNIFICANCE OF PROCALCITONIN LEVELS IN THE TREATMENT OF PATIENTS WITH COVID-19

62 -9 (59) 2023 — Oblokulov Abdurashid Rakhimovich — THE SIGNIFICANCE OF PROCALCITONIN LEVELS IN THE TREATMENT OF PATIENTS WITH COVID-19

THE SIGNIFICANCE OF PROCALCITONIN LEVELS IN THE TREATMENT OF PATIENTS WITH COVID-19

Oblokulov Abdurashid Rakhimovich Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The article discusses the literature data on the significance of commonly accepted methods for diagnosing bacterial infection, with an emphasis on laboratory presence / absence tests. In everyday practice, the likelihood of bacterial coinfection in patients with COVID-19 is assessed by clinical presentation of the disease and the results of standard laboratory tests and imaging methods. However, when viral respiratory infection develops, this approach does not always allow to diagnose bacterial coinfection with sufficient significance. This issue may be handled by available modern test systems, the use of a combination of signs or additional laboratory criteria (for example, procalcitonin), and the analysis of the overall clinical presentation by the doctor using knowledge about patient risk groups.

Key words: COVID-19, bacterial infection, diagnosis, procalcitonin

First page

340

Last page

345

For citation: Oblokulov Abdurashid Rakhimovich – THE SIGNIFICANCE OF PROCALCITONIN LEVELS IN THE TREATMENT OF PATIENTS WITH COVID-19 //New Day in Medicine 2023 9(59): 340-345 https://newdaymedicine.com/index.php/2023/10/18/l-465/

LIST OF REFERENCES:

  1. Oblokulov A.R., Musaeva D.M., Elmuradova A.A. (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). // New Day in Medicine. №2 (30/2) p.110-115 Niyazov G.E.,
  2. Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients // New Day in Medicine. 2020;4(32):110-115.
  3. Harte, E.; Kumarasamysarma, S.; Phillips, B.; et al. Procalcitonin Values Fail to Track the Presence of Secondary Bacterial Infections in COVID-19 ICU Patients. //Antibiotics 2023;12:709.
  4. Langford B.J., So M., Raybardhan S., et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. //Clin. Microbiol. Infect. 2020;26(12):1622e9.
  5. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. //J. Infect. Aug. 2020;81(2):266-275.
  6. Rodríguez-Baño J., Rossolini G.M., Schultsz C., et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. Trans. R. Soc. //Trop. Med. Hyg. Oct 1. 2021;115(10):1122-1129.
  7. Dhesi Z., Enne V.I., Brealey D., et al. Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test [preprint]. medrXiv; 2020 [accessed 2021 July 13].
  8. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and meta-analysis. //J. Infect. Aug. 2020;81(2):266-275.
  9. Кароли Н.А., Апаркина А.В., Григорьева Е.В., и др. COVID-19 и антибактериальная терапия на стационарном этапе: кому, когда, зачем? //Пульмонология. 2021;31(6):701–709. DOI: 10.18093/0869-0189-2021-31-6-701-709.
  10. Samprathi M, Jayashree M: Biomarkers in COVID-19: An up-to-date review. Front Pediatr. 2020;8:607647. 10.3389/fped.2020.607647
  11. Rothe K., Feihl S., Schneider J., et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. //Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(4):859-869.
  12. Williams E.J., Mair L., de Silva T.I., et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. //J. Hosp. Infect. 2021;110:103-107.
  13. May M., Chang M., Dietz D., et al. Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with coronavirus disease 2019. Antimicrob. Agents Chemother. 2021;65(4):e02167-20.
  14. Schuetz P et al. (2018) Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials, Expert Review of Anti-infective Therapy, 16:7, 555-564, doi.org/10.1080/14787210.2018.1496331
  15. Oblokulov A.R., Husenova Z.Z., Ergashev M.M. Procalcitonin as an indicator of antibacterial therapy in covid-19 //Annals of the Romanian Society for Cell Biology. 2021;5220-5224.
  16. Schuetz, P.; Wirz, Y.; Sager, R.; et al. Effect of Procalcitonin-guided Antibiotic Treatment on Mortality in Acute Respiratory Infections: A patient level meta-analysis. Lancet Infect. Dis. 2018;18:95-107.
  17. Vazzana N.; Dipaola F.; Ognibene S. Procalcitonin and Secondary Bacterial Infections in OVID-19: Association with Disease Severity and Outcomes. Acta Clinica Belgica. 2020;77:268-272.
  18. Powell, N.; Howard, P.; Llewelyn, M.J.; et al. Use of Procalcitonin During the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study. Antibiotics 2021;10:516.
  19. Llewelyn M.J.; Grozeva D.; Howard P.; et al. Impact of introducing Procalcitonin testing on antibiotic usage in acute NHS hospitals during the first wave of COVID-19 in the UK: A controlled interrupted time series analysis of organization-level data. //J. Antimicrob. Chemother. 2022;77:189-1196.
  20. Williams E.J.; Mair L.; de Silva T.I.; et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-COV-2 infection: A retrospective cohort study. //J. Hosp. Infect. 2021;110:103-107.

file

download